Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Genitourinary 3

Conditions

Urinary Bladder Neoplasms 41Non-Muscle Invasive Bladder Neoplasms 25Colorectal Neoplasms 21Carcinoma, Transitional Cell 17Anus Neoplasms 17Neoplasm Metastasis 12Carcinoma, Hepatocellular 11Appendiceal Neoplasms 11Stomach Neoplasms 10Peritoneal Neoplasms 9Pancreatic Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Neoplasms 7Lung Neoplasms 6Colonic Neoplasms 6Rectal Neoplasms 5Liver Neoplasms 5Urologic Neoplasms 4Sarcoma 4Carcinoma 4Anal Canal Carcinoma 4Urologic Diseases 3Urogenital Neoplasms 3Urinary Bladder Diseases 3Recurrence 3Pseudomyxoma Peritonei 3Ovarian Neoplasms 3Neoplasms by Site 3Mesothelioma, Malignant 3Gastrointestinal Neoplasms 3

Interventions

pembrolizumab 5padeliporfin 5Nivolumab 5fludarabine 4aldesleukin 4Ipilimumab 4Cyclophosphamide 4atezolizumab 3Sunitinib 3Specimen Handling 3Paclitaxel 3Mitomycin 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Drug Therapy 3Carboplatin 3Biopsy 3Abiraterone Acetate 3vedolizumab 2olaparib 2niraparib 2motexafin gadolinium 2enfortumab vedotin 2darolutamide 2cabozantinib 2anlotinib 2abiraterone 2Therapeutics 2Suspensions 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Urogenital Neoplasms × Mitomycin × Clear all
NCT07566156 2026-05-11

EV-309

Astellas Pharma Inc

Phase 3 Recruiting
390 enrolled
Genitourinary

Urogenital Diseases, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Female Urogenital Diseases, Male Urogenital Diseases

NCT05874921 2025-02-28

uTRACT

UroGen Pharma Ltd.

Recruiting
400 enrolled
Genitourinary

Carcinoma, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Recurrence, Urogenital Neoplasms, Urologic Neoplasms

NCT01200992 2017-08-24

EMBARC-RF

Bioniche Life Sciences Inc.

Phase 3 Terminated
84 enrolled 7 charts
Genitourinary

Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Mycobacterium Infections, Neoplasm Recurrence, Local, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡